Enavogliflozin was found to be a well-tolerated and effective sodium glucose co-transporter-2 inhibitor (SGLT2i). Over 24 weeks of treatment, enavogliflozin had superior glycemic efficacy and adverse events similar to dapagliflozin.
Enavogliflozin is a novel SGLT2 inhibitor developed in South Korea. Deep Dutta, Department of Endocrinology, Center for Endocrinology Diabetes Arthritis & Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, India, and colleagues conducted the meta-analysis to analyze the safety and efficacy of enavogliflozin in type 2 diabetes.
For this purpose, the researchers systematically searched the electronic databases for randomized controlled trials (RCTs) involving patients with type 2 diabetes receiving enavogliflozin in treatment-arm, and placebo/any other medicine in control-arm.
The study's primary outcome was to evaluate changes in HbA1C (glycosylated haemoglobin). Secondary outcomes were to evaluate changes in 2-h post-prandial glucose (2-h PPG), fasting glucose (FPG), weight, blood pressure (BP), lipids, and adverse events.
Data was analyzed from 4 trials comprising 684 patients for clinical outcomes over 12–24 weeks of clinical use.
The study led to the following findings:
- Compared to placebo, patients receiving enavogliflozin had significantly lower HbA1c [MD -0.76%], FPG [MD -2.12 mmol/l], body weight [MD-1.37 kgs], systolic BP [MD-4.99 mm Hg], diastolic BP [MD-3.09 mm Hg].
- Treatment-emergent adverse events [OR1.16], serious adverse events [OR1.81], urinary infections [OR1.37] and genital infections [OR 3.07] were comparable.
- Compared to dapagliflozin patients receiving enavogliflozin had significantly lower HbA1c [MD-0.06%], FPG [MD-0.19 mmol/l], body-weight [MD-0.20 kgs], diastolic BP [MD -0.92 mm Hg] and significantly higher urine glucose creatinine ratio [MD 16.69 g/g].
"The findings showed enavogliflozin to be a well-tolerated and effective SGLT2 inhibitor for type 2 diabetes and may be superior to dapagliflozin about certain clinical aspects over six months of clinical use," the researchers concluded.
Reference:
Dutta, D., Harish, B., Anne, B., & Nagendra, L. (2023). Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 17(8), 102816. https://doi.org/10.1016/j.dsx.2023.102816
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.